Diot P, Lemarié E, Baulieu J L, Pascal S, Vaillant L, Revillard J P, Binz H, Normier G, Le Pape A
Laboratoire de Biophysique Cellulaire, INSERM U316, Faculté de Médecine de Tours, France.
Chest. 1992 Sep;102(3):670-6. doi: 10.1378/chest.102.3.670.
Scintigraphy with radiolabeled J001 as a ligand for macrophage targeting is a new approach for sarcoidosis imaging. J001 is a fully characterized acylated peptido-poly (1,3) galactoside isolated from Klebsiella membrane proteoglycans and able to bind electively recruited macrophages. Its physiochemical properties allow rapid absorption by the respiratory tract when this agent, labeled by 99m technetium, is administered as an aerosol. Images are obtained within 3 to 5 h after inhalation. In the present study, we determined the ability of J001 scintigraphy to localize areas of sarcoidosis involvement in 22 patients compared with gallium scanning in ten of them. Nineteen patients underwent bronchoalveolar lavage (BAL) and serum angiotensin-converting enzyme (ACE) assay. J001 scintigraphy was also performed on a control group of six patients with extrathoracic melanoma, in whom J001 scintigraphy was used to evaluate the cutaneous extent of the tumor and the lymph node involvement. In this control group, no fixation appeared in the thoracic area. In the sarcoidosis group, 18 positive results were observed. One stage 0 patient had a mediastinal fixation. Five of the six stage 1 patients had a fixation located in the mediastinum, the lungs, and the wrists. Five of the six stage 2 patients had positive foci located in the mediastinum or the lung areas and in the myocardium in one of them. Six of the nine stage 3 patients had positive J001 scintigraphy occurring in the lungs and/or the mediastinum. One patient had a fixation on the main bronchi. J001 scintigraphy and gallium scanning, performed in ten patients, were positive in seven of them. There were discrepancies between the BAL results and J001 scintigraphy, as well as between the ACE results and J001 scintigraphy. In conclusion, 99mTc-J001 scintigraphy appears to be a sensitive and rapid technique for the imaging of thoracic sarcoidosis at the three stages of the disease.
用放射性标记的J001作为巨噬细胞靶向配体进行闪烁扫描是结节病成像的一种新方法。J001是一种从克雷伯菌膜蛋白聚糖中分离出来的、特性完全明确的酰化肽聚（1,3）半乳糖苷，能够选择性地结合募集来的巨噬细胞。当用99m锝标记的这种试剂以气雾剂形式给药时，其物理化学性质使其能够被呼吸道快速吸收。吸入后3至5小时内即可获得图像。在本研究中，我们测定了22例患者中J001闪烁扫描定位结节病受累区域的能力，并与其中10例患者的镓扫描结果进行了比较。19例患者接受了支气管肺泡灌洗（BAL）和血清血管紧张素转换酶（ACE）检测。还对6例胸外黑色素瘤患者组成的对照组进行了J001闪烁扫描，在该组中，J001闪烁扫描用于评估肿瘤的皮肤范围和淋巴结受累情况。在这个对照组中，胸部区域未出现固定显像。在结节病组中，观察到18例阳性结果。1例0期患者有纵隔固定显像。6例1期患者中有5例的固定显像位于纵隔、肺部和腕部。6例2期患者中有5例的阳性病灶位于纵隔或肺部区域，其中1例位于心肌。9例3期患者中有6例的J001闪烁扫描在肺部和/或纵隔呈阳性。1例患者主支气管有固定显像。对10例患者进行的J001闪烁扫描和镓扫描，其中7例呈阳性。BAL结果与J001闪烁扫描结果之间，以及ACE结果与J001闪烁扫描结果之间存在差异。总之，99mTc-J001闪烁扫描似乎是一种用于疾病三个阶段的胸部结节病成像的灵敏且快速的技术。
